Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multiomics Dataset for the Cohort Study of Preclinical Pulmonary Fibrosis (PrePF)

ABSTRACT: Multiomics Dataset for the Cohort Study of Preclinical Pulmonary Fibrosis (PrePF)

PROVIDER: PRJNA853852 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

MoTrPAC Multiomics Dataset – Adult Humans – Restricted Access

Project description:MoTrPAC Multiomics Dataset – Adult Humans – Restricted Access

| PRJNA1425566 | ENA

MoTrPAC Multiomics Dataset – Adult Humans – Restricted Access

Project description:MoTrPAC Multiomics Dataset – Adult Humans – Restricted Access

| PRJNA1425567 | ENA

Airway metagenomes from the BWPR cohort – initial dataset

Project description:Airway metagenomes from the BWPR cohort – initial dataset

| PRJEB96268 | ENA

Airway metagenomes from the BWPR cohort – second dataset

Project description:Airway metagenomes from the BWPR cohort – second dataset

| PRJEB106505 | ENA

RNA sequencing of pancreatic adenocarcinoma (PDAC) xenograft samples

Project description:Pancreatic adenocarcinoma (PDAC) is one of the most lethal human malignancies and a major health problem. Patient-derived xenografts (PDX) are appearing as a prime approach for preclinical studies despite being insufficiently characterized as a model of the human disease and its diversity. We generated subcutaneous PDX from PDAC samples obtained either surgically or using diagnostic biopsies (endoscopic ultrasound guided fine needle aspirate). The extensive multiomics characterization of the xenografts demonstrated that PDX is a suitable model for preclinical studies, representing the diversity of the primary cancers. this dataset, describe the RNA sequencing data used in the multiomics study.

2017-12-12 | E-MTAB-5039 | biostudies-arrayexpress

An integrative multiomics framework for identification of therapeutic targets in pulmonary fibrosis [TimeSeries]

Project description:Pulmonary fibrosis (PF) is a progressive disease with a poor prognosis and lack of effective treatments. Therefore, identifying effective therapeutic modalities is required to improve outcome. However, the lack of predictive progressive disease biomarkers in the clinic causes a significant gap in the preclinical to clinical translational process. Here, we assessed and identified progressive alterations in pulmonary function, transcriptomics, and metabolomics in mice lungs at 7, 14, 21, and 28 days after a single dose of oropharyngeal bleomycin. By integrating multi-omics data, we identified two central gene subnetworks associated with multiple critical pathological changes in transcriptomics and metabolomics as well as pulmonary function. We presented a multi-omics-based framework to establish a translational link between the bleomycin-induced PF model in mice and human idiopathic pulmonary fibrosis to identify druggable targets and test therapeutic candidates. Our study also indicated peripheral CB1R antagonism as a rational therapeutic target for clinical translation in PF.

2023-04-11 | GSE213709 | GEO

An integrative multiomics framework for identification of therapeutic targets in pulmonary fibrosis [CB1R KO]

2023-04-11 | GSE217814 | GEO

miRNA profiling by high-throughput sequencing of pancreatic adenocarcinoma (PDAC) xenografts

Project description:A Cartes d'Identit des Tumeurs (CIT) project from the french Ligue Nationale Contre le Cancer (http://cit.ligue-cancer.net): Pancreatic adenocarcinoma (PDAC) is one of the most lethal human malignancies and a major health problem. Patient-derived xenografts (PDX) are appearing as a prime approach for preclinical studies despite being insufficiently characterized as a model of the human disease and its diversity. We generated subcutaneous PDX from PDAC samples obtained either surgically or using diagnostic biopsies (endoscopic ultrasound guided fine needle aspirate). The extensive multiomics characterization of the xenografts demonstrated that PDX is a suitable model for preclinical studies, representing the diversity of the primary cancers. the MultiOmicClassification variable indicates groups resulting from the analysis, and the CIMPclass, the CpG Island Methylator Phenotype as estimated by the methylation analysis. This dataset, describes the miRNA-Seq data used in the multiOmics analysis.

2017-12-12 | E-MTAB-5018 | biostudies-arrayexpress

An integrative multiomics framework for identification of therapeutic targets in pulmonary fibrosis

Project description:An integrative multiomics framework for identification of therapeutic targets in pulmonary fibrosis

| PRJNA900598 | ENA

Integrative Multiomics in the Lung Reveals a Protective Role of Asporin in Pulmonary Arterial Hypertension.

Project description:Integrative multiomics can elucidate pulmonary arterial hypertension (PAH) pathobiology but procuring human PAH lung samples is rare. Here, we leverage transcriptomic profiling and deep phenotyping of the largest multicenter PAH lung biobank to date (96 disease and 52 control) by integration with clinicopathologic data, genome-wide association studies, Bayesian regulatory networks, single-cell transcriptomics, and pharmacotranscriptomics. We identify two potentially protective gene network modules associated with vascular cells, and we validated ASPN, coding for asporin, as a key hub gene that is upregulated as a compensatory response to counteract PAH. Specifically, we find that asporin is upregulated in lungs and plasma of multiple independent PAH cohorts and correlates with reduced PAH severity. We show asporin inhibits proliferation and TGF-β/pSMAD2/3 signaling in pulmonary artery smooth muscle cells from PAH lungs. Finally, we demonstrate in Sugen-hypoxia rats that ASPN knockdown exacerbated PAH while recombinant asporin attenuated PAH. Our integrative systems biology approach to dissect the PAH lung transcriptome uncovered asporin as a novel protective target with therapeutic potential in PAH.

2024-05-22 | GSE254617 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data